Nuclear medicine imaging for the assessment of primary and recurrent head and neck carcinoma using routinely available tracers

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 30, Issue 12, 2003, Pages 1689-1700

  Vermeersch, Hubert ^a   Loose, David ^a   Ham, Hamphrey ^a   Otte, Andreas ^a   Van De Wiele, Christophe ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Conventional imaging; FDG PET; Head and neck; Squamous cell carcinoma

Indexed keywords

FLUORODEOXYGLUCOSE F 18; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; TETROFOSMIN TC 99M; THALLIUM 201;

CANCER STAGING; CERVICAL LYMPH NODE; DATA BASE; HEAD AND NECK CANCER; HUMAN; LYMPH NODE METASTASIS; MEDLINE; POSITRON EMISSION TOMOGRAPHY; RADIOISOTOPE DIAGNOSIS; RECEIVER OPERATING CHARACTERISTIC; RECURRENT CANCER; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SQUAMOUS CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; LYMPHATIC METASTASIS; NEOPLASM RECURRENCE, LOCAL; NUCLEAR MEDICINE; RADIOISOTOPES; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0346103814     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-003-1345-4     Document Type: Review

References (99)

1. Jacobs C. The internist in the management of head and neck cancer. Ann Intern Med 1990; 113:771-778.
2. Vokes E, Weichselbaum R, Lipman SM, et al. Head and neck cancer. N Engl J Med 1993; 328:184-194.
3. Ali S, Tiwari R, Snow G. False positive and false negative neck nodes. Head Neck 1985; 8:78-82.
4. Bocca E, Calearo C, de Vincentis I, et al. Occult metastases in cancer of the larynx and their relationship to clinical and histological aspects of the primary tumor: a four-year multicentric research. Laryngoscope 1984; 94:1086-1090.
5. Friedman M, Shelton VK, Mafee M, et al. Metastatic neck disease. Evaluation by computed tomography. Arch Otolaryngol 1984; 110:443-447.
6. Madison M, Remley K, Latchaw R, Mitchell S. Radiological diagnosis and staging of head and neck squamous cell carcinoma. Radiol Clin North Am 1994; 32:163-181.
7. van den Brekel M, Castelijns J, Stel H, et al. Cervical lymph node metastases: assessment of radiologic criteria. Radiology 1981:180:457-461.
8. Gritzmann N, Czembriek H, Hajek P, et al. Sonografie bei cervikalen lymphknotenmetastasen. Radiologie 1987; 27:118-122.
9. Schwartz LH, Oszahin M, Zhang G, et al. Synchronous and metachronous head and neck carcinomas. Cancer 1994; 74:1933-1938.
10. Parker J, Hill J. Panendoscopy in screening for synchronous primary malignancies. Laryngoscope 1988; 98:147-149.
11. Hordijk G, Bruggink T, Ravasz L. Panendoscopy: a valuable procedure. Laryngol Head Neck Surg 1989; 101:426-428.
12. Dhooge I, de Vos J, Albers F. Panendoscopy as a screening procedure for simultaneous primary tumors in head and neck cancer. EurArch Otorhinolaryngol 1996; 253:319-324.
13. McGarry G, MacKenzie K, Periasamy P, McGurk F, Gatehouse S. Multiple primary malignant tumors in patients with head and neck cancer: the implications for follow-up. Clin Otolaryngol 1992; 17:558-562.
14. Calhoun K, Fulmezr P, Weiss R, Hokanson J. Distant metastases from head and neck cancers. Laryngoscope 1994; 104:1199-1205.
15. Troell R, Terris D. Detection of metastases from head and neck cancers. Laryngoscope 1995; 105:247-250.
16. Shingaki S, Suzuki I, Kobayashi T, Nakajima T. Predicting factors for distant metastases in head and neck carcinomas: an analysis of 103 patients with locoregional control. J Oral Maxillofac Surg 1996; 54:853-857.
17. Lihschitz H, North L. Metastatic disease: pulmonary metastases. Radiol Clin North Am 1982; 20:437-451.
18. Milla N, Ito K, Ikeda M, Nakamura K, Hiroshe M, Ishigaki T. Fundamental and clinical evaluation of chest tomography imaging in detectability of pulmonary nodules. Nagoya J Med Sci 1994; 57:127-132.
19. Johns M, Peters G. Staging in specific anatomical sites. In: Wites RE ed. Manual of oncology therapeutics. Philadelphia: Lippincott; 1991/1992:37-46.
20. Drost P, Schrader M, Talanow D. Value of abdominal ultrasound and skeletal scintigraphy in TNM classification of tumors in the head and neck area. HNO 1994; 42:418-421.
21. Ampil F, Wood M, Chin H, Hoasjoe D, Aarstad R, Hilton D. Screening bone scintigraphy in the staging of locally advanced head and neck cancer. J Craniomaxillofac Surg 1995; 23:115-118.
22. Parker SL, Tong T, Bolden S, et al. Cancer statistics 1996. CA Cancer J Clin 1996; 46:5-27.
23. Volkes EE, Weichselbaum RR, Lipman SM, et al. Head and neck cancer. N Engl J Med 1993; 328:184-194.
24. Forastiere AA. Overview of platinum chemotherapy in head and neck cancer. Semin Oncol 1994; 21:20-27.
25. Aisner J, Jacobs M, Sinabaldi V, et al. Chemoradiotherapy for the treatment of regionally advanced head and neck cancers. Semin Oncol 1994; 21:35-44.
26. Panje WR, Namon AJ, Vokes E, et al. Surgical management of the head and neck cancer patient following concomitant multimodality therapy. Laryngoscope 1995; 105:97-101.
27. Itam J, Mikata A, Arimizu N, et al. Radiation therapy of the nasopharyngeal cancer and its prognostic factors. Strahlether Onkol 1988; 164:46-50.
28. Kayano T, Burant CF, Fukumoto H, et al. Human facilitative glucose transporters. Isolation, functional characterization, and gene localization of cDNAs encoding an isoform (GLUT5) expressed in small intestine, kidney, muscle, and adipose tissue and an unusual glucose transporter pseudogene-like sequence (GLUT6). J Biol Chem 1990; 265:13276-13282.
29. Gould GW, Holman GD. The glucose transporter family: structure, function and tissue-specific expression. Biochem J 1993; 295:329-341.
30. Warburg O. The metabolism of tumours. Arnold Constable, London 1930
31. Mathupala SP, Rempel A, Pedersen PL. Aberrant glycolytic metabolism of cancer cells: a remarkable coordination of genetic, transcriptional, post-translational, and mutational events that lead to a critical role for type II hexokinase. J Bioenerg Biomembr 1997; 29:339-343.
32. Mathupala SP, Rempel A, Pedersen PL. Glucose catabolism in cancer cells: identification and characterization of a marked activation response of the type II hexokinase gene to hypoxic conditions. J Biol Chem 2001; 276:43407-43412.
33. Burgman P, Odonoghue JA, Humm JL, et al. Hypoxia-induced increase in FDG uptake in MCF7 cells. J Nucl Med 2001; 42:170-175.
34. Reisser C, Eichhorn K, Herold-Mende C, et al. Expression of facilitative glucose transport proteins during development of squamous cell carcinomas of the head and neck. Int J Cancer 1999; 80:194-198.
35. Manolidis S, Donald PJ, Volk P, et al. The use of positron emission tomography scanning in occult and recurrent head and neck cancer. Acta Otolarnygol Suppl 1998; 534:1-11.
36. Nowak B, Di-Martino E, Janicke S, et al. Diagnostic evaluation of malignant head and neck cancer by F-18-FDG PET compared to CT/MRI. Nuklearmedizin 1999; 38:312-318.
37. Di-Martino E, Nowak B, Hassan HA, et al. Diagnosis and staging of head and neck cancer: a comparison of modern imaging modalities (positron emission tomography, computed tomography, color-coded duplex sonography) with panendoscopic and histopathologic findings. Arch Otolarnygol Head Neck Surg 2000; 126:1457-1461.
38. Popperl G, Lang S, Dagdelen O, et al. Correlation of FDG-PET and MRI/CT with histopathology in primary diagnosis, lymph node staging and diagnosis of recurrency of head and neck cancer. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 2002; 174:714-720.
39. Benchaou M, Lehmann W, Slosman DO, et al. The role of FDG-PET in the preoperative assessment of N-staging in head and neck cancer. Acta Otolaryngol 1996; 116:332-335.
40. Wong WL, Chevretton EB, McGurk M, et al. A prospective study of PET-FDG imaging for the assessment of head and neck squamous cell carcinoma. Clin Otolaryngol 1997; 22:209-214.
41. 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med 1998; 25:1255-1260.
42. Mattei R, Rubello D, Ferlin G, et al. Positron emission tomography (PET) with 18-fluorodeoxyglucose (FDG) in the diagnosis and preoperative staging of head and neck tumors: a prospective study. Acta Otorhinolaryngol Ital 1998; 18:387-391.
43. Stuckensen T, Kovacs AF, Adams S, et al. Staging of the neck in patients with oral cavity squamous cell carcinomas: a prospective comparison of PET, ultrasound, CT and MRI. J Craniomaxillofac Surg 2000; 28:319-324.
44. 18F-fluorodeoxyglucose positron emission tomography and computed tomography with histopathologic correlation in the initial staging of head and neck cancer. Ann Surg 2002; 236:208-217.
45. Laubenbacher C, Saumweber D, Wagner-Manslau C, et al. Comparison of fluorine-18-fluorodeoxyglucose PET, MRI and endoscopy for staging head and neck squamous-cell carcinomas. J Nucl Med 1995; 36:1747-1757.
46. Braams JW, Pruim J, Freling NJ, et al. Detection of lymph node metastases of squamous-cell cancer of the head and neck with FDG-PET and MRI. J Nucl Med 1995; 36:211-216.
47. McGuirt WF, Williams DW 3rd, Keyes JW Jr, et al. A comparative diagnostic study of head and neck nodal metastases using positron emission tomography. Laryngoscope 1995; 105:373-375.
48. 18FDG-PET for the assessment of primary head and neck tumors: clinical, computed tomography, and histopathological correlation in 38 patients. Laryngoscope 1998; 108:1578-1583.
49. Rege S, Maass A, Chaiken L, et al. Use of positron emission tomography with fluorodeoxyglucose in patients with extracranial head and neck cancers. Cancer 1994; 73:3047-3058.
50. Myers LL, Wax MK. Positron emission tomography in the evaluation of the negative neck in patients with oral cavity cancer: J Otolaryngol 1998; 27:342-347.
51. 18F-FDG PET: a comparison with conventional methods. Eur J Nucl Med 2001; 28:816-821.
52. Erkal HS, Mendenhall WM, Amdur RJ, et al. Synchronous and metachronous squamous cell carcinomas of the head and neck mucosal sites. J Clin Oncol 2001; 19:1358-1362.
53. Wax MK, Myers LL, Gabalski EC, et al. Positron emission tomography in the evaluation of synchronous lung lesions in patients with untreated head and neck cancer. Arch Otolaryngol Head Neck Surg 2002; 128:703-707.
54. Keyes JW, Chen MY, Watson NE, et al. FDG PET evaluation of head and neck cancer: value of imaging the thorax. Head Neck 2000; 22:105-110.
55. Teknos TN, Rosenthal EL, Lee D, et al. Positron emission tomography in the evaluation of stage III and IV head and neck cancer. Head Neck 2001; 23:1056-1060.
56. Mancuso AA. Imaging in patients with head and neck cancer. In: Million RR, Cassisi NJ, eds. Management of head and neck cancer: a multidisciplinary approach. Philadelphia: Lippincott; 1994:43-59.
57. Som PM, Biller HF. Computed tomography of the neck in the postoperative patient: radical neck dissection and the myocutaneous flap. Radiology 1983; 148:157-160.
58. DiSantis DJ, Balfe DM, Hayden RE, et al. The neck after total laryngectomy: CT study. Radiology 1984; 153:713-717.
59. Cheon GJ, Chung JK, So Y, et al. Diagnostic accuracy of F-18 FDG-PET in the assessment of post-therapeutic recurrence of head and neck cancer. Clin Positron Imaging 1999; 2:197-204.
60. 18F-fluoro-2-deoxy-D-glucose positron emission tomography. Laryngoscope 1999; 109:970-975.
61. Lapela M, Eigtved A, Jyrkkio S, et al. Experience in qualitative and quantitative FDG PET in follow-up of patients with suspected recurrence from head and neck cancer. Eur J Cancer 2000; 36:858-867.
62. Lowe VJ, Boyd JH, Dunphy FR, et al. Surveillance for recurrent head and neck cancer using positron emission tomography. J Clin Oncol 2000; 18:651-658.
63. Lonneux M, Lawson G, Ide C, et al. Positron emission tomography with fluorodeoxyglucose for suspected head and neck tumor recurrence in the symptomatic patient. Laryngoscope 2000; 110:1493-1497.
64. Haenggeli CA, Dulguerov P, Slosman D, et al. Value of positron emission tomography with 18-fluorodeoxyglucose (FDG-PET) in early detection of residual tumor in oro-pharyngeallaryngeal carcinoma. Schweiz Med Wochenschr Suppl 2000; 116:8S-11S.
65. Li P, Zhuang H, Mozley PD, et al. Evaluation of recurrent squamous cell carcinoma of the head and neck with FDG positron emission tomography. Clin Nucl Med 2001; 26:131-135.
66. Anzai Y, Caroll WR, Quint DJ, et al. Recurrence of head and neck cancer after surgery or irradiation: prospective comparison of 2-deoxy-2-[F18]fluoro-D-glucose PET and MR imaging diagnoses. Radiology 1996; 200:135-141.
67. Greven KM, Williams DW, Keyes JW, et al. Can positron emission tomography distinguish tumor recurrence from irradiation sequelae in patients treated for larynx cancer? Cancer J Sci Am 1997; 3:353-357.
68. 18F-FDG) in head and neck cancer. J Laryngol Otol 1999; 113:548-554.
69. Million RR, Cassisi NJ, Mancuso AA. The unknown primary. In: Million RR, Cassisi NJ, eds. Management of head and neck cancer. A multidisciplinary approach, 2nd edn. Philadelphia: Lippincott; 1994:311-321.
70. De Braud F, Al-Sarraf M. Diagnosis and management of squamous cell carcinoma of unknown primary tumor site of the neck. Semin Oncol 1993; 20:273-278.
71. Kole AC, Nieweg OE, Pruim J, et al. Detection of unknown occult primary tumors using positron emission tomography. Cancer 1998; 82:160-166.
72. Braams JW, Pruim J, Kole AC, et al. Detection of unknown primary head and neck tumors by using positron emission tomography. Int J Oral Maxillofacial Surg 1997; 26:112-115.
73. Aasar OS, Fischbein NJ, Caputo GR, et al. Metastatic head and neck cancer: role and usefulness of FDG PET in locating occult primary tumors. Radiology 1999; 210:177-181.
74. 18F-FDG whole body positron emission tomography (PET) in patients with unknown primary tumors (UPT). Eur J Cancer 1999; 35:1076-1082.
75. Safa AA, Tran LM, Rege S, et al. The role of positron emission tomography in occult primary head and neck cancers. Cancer J 1999; 5:214-218.
76. Jungehulsing M, Scheidhauer K, Damm M, et al. 2[F]-fluoro-2-deoxy-D-glucose positron emission tomography is a sensitive tool for the detection of occult primary cancer (carcinoma of unknown primary syndrome) with head and neck lymph node manifestation. Otolaryngol Head Neck Surg 2000; 123:294-301.
77. Greven KM, Keyes JJ, Williams DR, et al. Occult primary tumors of the head and neck: lack of benefit from positron emission tomography imaging with 2-[F-18]fluoro-2-deoxy-D-glucose. Cancer 1999; 86:114-118.
78. +) activated ATP-ase of rabbit kidney. Biochem Biophys Acta 1968; 159:160-166.
79. Cox PH, Belfer AJ, van der Pompe WB. Thallium-201 chloride uptake in tumours, a possible complication in heart scintigraphy. Br J Radiol 1976; 49:767-768.
80. 201T1 SPECT for evaluating head and neck cancer. Ann Nucl Med 1996; 10:105-111.
81. Gregor RT, Valdes-Olmos R, Koops W, et al. Preliminary experience with thallous chloride T1 201-labeled single-photon emission computed tomography scanning in head and neck cancer. Arch Otolaryngol Head Neck Surg 1996; 122:509-514.
82. Guney E, Yigitbasi OG, Tutus A, et al. Value of thallium-201 scintigraphy for primary tumour detection in patients with malignant neck masses. Eur J Nucl Med 1998; 25:431-434.
83. van Veen SA, Balm AJ, Valdes-Olmos RA, et al. Occult primary tumors of the head and neck: accuracy of thallium 201 single-photon emission computed tomography and computed tomography and/or magnetic resonance imaging. Arch Otolaryngol Head Neck Surg 2001; 127:406-411.
84. Mukherji SK, Gapany M, Phillips D, et al. Thallium-201 single-photon emission CT versus CT for the detection of recurrent squamous cell carcinoma of the head and neck. Am J Neuroradiol 1999; 20:1215-1220.
85. 99mTc-sestamibi in oncology. Tumori 1996; 82:12-21.
86. Wang SJ, Hsu CY, Lin WY, et al. Comparison of TI-201 and Tc-99m MIBI SPECT imaging in nasopharyngeal carcinoma. Clin Nucl Med 1995; 20:800-802.
87. 201T1-thallous chloride in tumour cells: role of P-glycoprotein. Q J Nucl Med 1995; 39:122-128.
88. Pui MH, Du JQ, Yueh TC, et al. Imaging of nasopharyngeal carcinoma with Tc-99m MIBI. Clin Nucl Med 1998; 23:29-32.
89. Sun SS, Tsai SC, Ho YJ, et al. Detection of cervical lymph node metastases in nasopharyngeal carcinomas: comparison between technetium-99m methoxyisobutylisonitrile single photon emission computed tomography and computed tomography. Anticancer Res 2001; 21:1307-1310.
90. Tai CJ, Shiau YC, Tsai MH, et al. Detection of cervical lymph node metastases in nasopharyngeal carcinomas: comparison between technetium-99m methoxyisobutylisonitrile single photon emission computed tomography and magnetic resonance imaging. Neoplasma 2002; 49:251-254.
91. Shiau YC, Tsai SC, Ho YJ, et al. Comparison of technetium-99m methoxyisobutylisonitrile single photon emission computed tomography and computed tomography to detect recurrent or residual nasopharyngeal carcinomas after radiotherapy. Anticancer Res 2001; 21:2213-2217.
92. Kao CH, Shiau YC, Shen YY, et al. Detection of recurrent or persistent nasopharyngeal carcinomas after radiotherapy with technetium-99m methoxyisobutylisonitrile single photon emission computed tomography and computed tomography: comparison with 18-fluoro-2-deoxyglucose positron emission tomography. Cancer 2002; 94:1981-1986.
93. Shen YY, Kao CH, Changlai SP, et al. Detection of nasopharyngeal carcinoma with head and neck Tc-99m tetrofosmin SPECT imaging. Clin Nucl Med 1998; 23:305-308.
94. Shiau YC, Tsai SC, Wang JJ, et al. Detection of cervical lymph node metastases of nasopharyngeal carcinomas with technetium-99m tetrofosmin single photon emission computed tomography and comparison with computed tomography. Anticancer Res 2001; 21:723-726.
95. Kao CH, Tsai SC, Wang JJ, et al. Comparing 18-fluoro-2-deoxyglucose positron emission tomography with a combination of technetium 99m tetrofosmin single photon emission computed tomography and computed tomography to detect recurrent or persistent nasopharyngeal carcinomas after radiotherapy. Cancer 2001; 92:434-439.
96. Kostakoglu L, Uysal U, Ozyar E, et al. A comparative study of technetium-99m sestamibi and technetium-99m tetrofosmin single-photon tomography in the detection of nasopharyngeal carcinoma. Eur J Nucl Med 1997; 24:621-628.
97. 18F-fluorodeoxyglucose in the initial staging of nodal negative oral and oropharyngeal squamous cell carcinoma. Head Neck 2002; 24:345-349.
98. Hyde N, Prvulovich E, Newman L, Waddington W, Visvikis D, Ell P. A new approach to pre-treatment assessment of the NO neck in oral squamous cell carcinoma: the role of sentinel node biopsy and positron emission tomography. Oral Oncol 2003; 39:350-360.
99. Chao KS, Bosch WR, Mutic S, et al. A novel approach to overcome hypoxic tumor resistance: Cu-ASTM-guided intensity-modulated radiation therapy. Int J Radiat Biol Oncol Phys 2001; 49:1171-1182.